USC scientists create a temperature-stable vaccine for use in developing countries where refrigeration may be unavailable
USC researchers have developed a polio vaccine that doesn’t require refrigeration, meaning it could someday be used all over the world to deliver the final blow to this longtime foe.
The vaccine, which was freeze-dried into a powder, kept at room temperature for four weeks and then rehydrated, offered full protection against the polio virus when tested in mice.
Stabilization is not rocket science, so most academics don’t pay much attention to this field.
“Stabilization is not rocket science, so most academics don’t pay much attention to this field,” said the study’s first author, Woo-Jin Shin, a fellow in the lab of Jae Jung, chair of the Department of Molecular Microbiology and Immunology at the Keck School of Medicine of USC. “However, no matter how wonderful a drug or vaccine is, if it isn’t stable enough to be transported, it doesn’t do anyone much good.”
The study appears in the Nov. 27 issue of the journal mBio.
Polio is on the brink of complete eradication, with just 22 reported cases worldwide in 2017. The highly infectious disease, which causes lifelong paralysis and disability mostly in young children, is a fading memory in many places. Yet in countries where vaccination rates are spotty, young children are at risk.
The biggest hitch to complete eradication has been creating a temperature-stable vaccine for use in developing countries where refrigeration may be unavailable. Recent polio cases have been reported in Nigeria, Papua New Guinea, Syria and Pakistan.
Other freeze-dried vaccines
In the United States, the polio epidemic reached its height in the 1950s. In 1957, mass immunization brought the annual number of cases down from 58,000 to 5,600. Since 1979, no cases of polio have originated in the United States.
By removing moisture through freeze-drying, researchers have created temperature-stable vaccines for measles, typhoid and meningococcal disease. But scientists haven’t been able to make a polio vaccine that retains potency through freeze-drying and rehydration.
Shin and his colleagues used two lab techniques — liquid chromatography and high-throughput screening — that allowed them to analyze a high volume of ingredients and formulations until they found one that worked.
Jung’s hope is that a foundation or company will take over the project to pay for human studies and bring the injectable vaccine onto the market.
In addition to Shin, the study’s authors are Daiki Hara and Jae Jung of the Keck School of Medicine, and Francisca Gbormittah, Hana Chang and Byeong S. Chang of Integrity Bio, a company that specializes in biologics — medicines made from substances found in living things.
Back story: During dinner three years ago, Jung and his college buddy Chang, CEO of Integrity Bio, decided to bring together Jung’s virology expertise with Chang’s expertise in stabilization. Chang paid Shin’s salary, and Jung provided supplies.
“He and I decided to do this as we are getting old and we need to directly contribute to human health and life,” Jung said. “Creative ideas always start with food and drinks.”
The Latest on: Temperature-stable vaccine
via Google News
The Latest on: Temperature-stable vaccine
- Vaxart, Inc. Set to Join Russell 3000® Indexon June 24, 2020 at 3:06 pm
Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of May 8, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index, which remains in ...
- Vaxart, Inc. to Present at the H.C. Wainwright Virtual Fireside Chat Serieson June 23, 2020 at 5:13 am
Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and development, ...
- Synthetic peptide could be an effective COVID-19 treatment and SARS-CoV-2 vaccineon June 21, 2020 at 10:48 pm
Vaccines currently in development face the dual challenge ... Importantly, Ligandal’s peptide has advantages over other technologies in development because it is room temperature stable, meaning it ...
- Genetic Medicine will be the Solution to COVID-19, and Ligandal is Leading the wayon June 18, 2020 at 10:20 pm
Ligandal, one of the world's leading genetic medicine companies, has modelled a synthetic peptide that could be an effective COVID-19 treatment and SARS-CoV-2 vaccine. Peptides are strings of amino ...
- Genetic Medicine will be the Solution to COVID-19, and Ligandal is Leading the wayon June 18, 2020 at 2:25 pm
SAN FRANCISCO, June 18, 2020 /PRNewswire-PRWeb/ -- Vaccines currently in development ... in development because it is room temperature stable, meaning it represents a genuinely global solution ...
- Vaxart, Inc. Appoints New CEO to Accelerate Advancement of COVID-19 and Other Programson June 15, 2020 at 6:31 pm
Mr. Floroiu is a highly experienced biopharma executive with a proven track record of value creation, with substantial financial, strategic and operational experience in the vaccine and ...
- Vaxart, Inc. Appoints New CEO to Accelerate Advancement of COVID-19 and Other Programson June 15, 2020 at 12:30 am
June 15, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NasdaqCM: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral recombinant vaccines that are ...
- Vaxart to Present at the Jefferies Virtual Healthcare Conferenceon June 3, 2020 at 5:00 am
Vaxart’s vaccines are administered using a convenient room temperature-stable tablet, rather than by injection. Vaxart believes that tablet vaccines are easier to distribute and administer than ...
via Bing News